Mobilization of healthy donors with plerixafor affects the cellular composition of T-cell receptor (TCR)-αβ/CD19-depleted haploidentical stem cell grafts

Journal of Translational Medicine

Volumn 12, Issue 1, 2014, Pages

  Rutella, Sergio ^a,d   Filippini, Perla ^a   Bertaina, Valentina ^a   Li Pira, Giuseppina ^a   Altomare, Lidia ^a   Ceccarelli, Stefano ^a   Brescia, Letizia P ^a   Lucarelli, Barbarella ^a   Girolami, Elia ^a   Conflitti, Gianpiero ^a   Cefalo, Maria G ^a   Bertaina, Alice ^a   Corsetti, Tiziana ^a   Moretta, Lorenzo ^b,c   Locatelli, Franco ^a,c  

^a BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^b G GASLINI INSTITUTE   (Italy)

^c UNIVERSITY OF PAVIA   (Italy)

^d SIDRA MEDICAL AND RESEARCH CENTER   (Qatar)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; PLERIXAFOR; T LYMPHOCYTE RECEPTOR; T LYMPHOCYTE RECEPTOR ALPHABETA; UNCLASSIFIED DRUG; CD34 ANTIGEN; HETEROCYCLIC COMPOUND; LYMPHOCYTE ANTIGEN RECEPTOR;

APHERESIS; ARTICLE; BODY WEIGHT; CD16+ CELL; CD34+ HEMATOPOETIC STEM CELL; CELL COMPOSITION; CELL COUNT; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DOWN REGULATION; HAPLOIDENTICAL STEM CELL; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IMMUNOSUPPRESSIVE TREATMENT; MEMORY CELL; MEMORY T LYMPHOCYTE; MONOCYTE; MYELOID DENDRITIC CELL; NATURAL KILLER CELL; NORMAL HUMAN; PLASMACYTOID DENDRITIC CELL; PRO INFLAMMATORY 6 SULFO LACNAC+ DENDRITIC CELL; SINGLE DRUG DOSE; ALLOGRAFT; BLOOD GROUP TYPING; CHILD; CYTOLOGY; DONOR; HEMATOLOGIC DISEASES; IMMUNOLOGY; METABOLISM; PHYSIOLOGY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; STEM CELL MOBILIZATION;

ALLOGRAFTS; ANTIGENS, CD19; ANTIGENS, CD34; BLOOD GROUPING AND CROSSMATCHING; CELL COUNT; CHILD; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOLOGIC DISEASES; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HETEROCYCLIC COMPOUNDS; HUMANS; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; TISSUE DONORS;

EID: 84908177254     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/s12967-014-0240-z     Document Type: Article

References (55)

1. Locatelli F, Vinti L, Palumbo G, Rossi F, Bertaina A, Mastronuzzi A, Bernardo ME, Rutella S, Dellabona P, Giorgiani G, Moretta A, Moretta L. Strategies to optimize the outcome of children given T-cell depleted HLA-haploidentical hematopoietic stem cell transplantation. Best Pract Res Clin Haematol 2011, 24:339-349. 10.1016/j.beha.2011.04.004, 21925087.
2. Martelli MF, Di Ianni M, Ruggeri L, Pierini A, Falzetti F, Carotti A, Terenzi A, Reisner Y, Aversa F, Falini B, Velardi A. " Designed" grafts for HLA-haploidentical stem cell transplantation. Blood 2014, 123:967-973. 10.1182/blood-2013-10-531764, 24363403.
3. To LB, Levesque JP, Herbert KE. How I treat patients who mobilize hematopoietic stem cells poorly. Blood 2011, 118:4530-4540. 10.1182/blood-2011-06-318220, 21832280.
4. DiPersio JF, Uy GL, Yasothan U, Kirkpatrick P. Plerixafor. Nat Rev Drug Discov 2009, 8:105-106. 10.1038/nrd2819, 19180104.
5. Rutella S, Pierelli L, Bonanno G, Scambia G, Leone G, Rumi C. Homogeneous expression of CXC chemokine receptor 4 (CXCR4) on G-CSF-mobilized peripheral blood CD34+ cells. Blood 2000, 95:4015-4016. 10939797.
6. DiPersio JF, Micallef IN, Stiff PJ, Bolwell BJ, Maziarz RT, Jacobsen E, Nademanee A, McCarty J, Bridger G, Calandra G. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. J Clin Oncol 2009, 27:4767-4773. 10.1200/JCO.2008.20.7209, 19720922.
7. Nademanee AP, DiPersio JF, Maziarz RT, Stadtmauer EA, Micallef IN, Stiff PJ, Hsu FJ, Bridger G, Bolwell BJ. Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34+ hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34+ cell count: results of a subset analysis of a randomized trial. Biol Blood Marrow Transplant 2012, 18:1564-1572. 10.1016/j.bbmt.2012.05.017, 22683613.
8. Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu Rev Immunol 2003, 21:685-711. 10.1146/annurev.immunol.21.120601.141040, 12615891.
9. Ziegler-Heitbrock L, Ancuta P, Crowe S, Dalod M, Grau V, Hart DN, Leenen PJ, Liu YJ, MacPherson G, Randolph GJ, Scherberich J, Schmitz J, Shortman K, Sozzani S, Strobl H, Zembala M, Austyn JM, Lutz MB. Nomenclature of monocytes and dendritic cells in blood. Blood 2010, 116:e74-e80. 10.1182/blood-2010-02-258558, 20628149.
10. Jongbloed SL, Kassianos AJ, McDonald KJ, Clark GJ, Ju X, Angel CE, Chen CJ, Dunbar PR, Wadley RB, Jeet V, Vulink AJ, Hart DN, Radford KJ. Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens. J Exp Med 2010, 207:1247-1260. 10.1084/jem.20092140, 20479116.
11. Bachem A, Guttler S, Hartung E, Ebstein F, Schaefer M, Tannert A, Salama A, Movassaghi K, Opitz C, Mages HW, Henn V, Kloetzel PM, Gurka S, Kroczek RA. Superior antigen cross-presentation and XCR1 expression define human CD11c+CD141+ cells as homologues of mouse CD8+ dendritic cells. J Exp Med 2010, 207:1273-1281. 10.1084/jem.20100348, 20479115.
12. Nizzoli G, Krietsch J, Weick A, Steinfelder S, Facciotti F, Gruarin P, Bianco A, Steckel B, Moro M, Crosti M, Romagnani C, Stolzel K, Torretta S, Pignataro L, Scheibenbogen C, Neddermann P, De Francesco R, Abrignani S, Geginat J. Human CD1c+ dendritic cells secrete high levels of IL-12 and potently prime cytotoxic T-cell responses. Blood 2013, 122:932-942. 10.1182/blood-2013-04-495424, 23794066.
13. Anderlini P, Champlin RE. Biologic and molecular effects of granulocyte colony-stimulating factor in healthy individuals: recent findings and current challenges. Blood 2008, 111:1767-1772. 10.1182/blood-2007-07-097543, 18057230.
14. Rutella S, Zavala F, Danese S, Kared H, Leone G. Granulocyte colony-stimulating factor: a novel mediator of T cell tolerance. J Immunol 2005, 175:7085-7091. 10.4049/jimmunol.175.11.7085, 16301609.
15. Pan L, Delmonte J, Jalonen CK, Ferrara JL. Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease. Blood 1995, 86:4422-4429. 8541530.
16. Sloand EM, Kim S, Maciejewski JP, Van Rhee F, Chaudhuri A, Barrett J, Young NS. Pharmacologic doses of granulocyte colony-stimulating factor affect cytokine production by lymphocytes in vitro and in vivo. Blood 2000, 95:2269-2274. 10733495.
17. Rutella S, Pierelli L, Bonanno G, Sica S, Ameglio F, Capoluongo E, Mariotti A, Scambia G, d'Onofrio G, Leone G. Role for granulocyte colony-stimulating factor in the generation of human T regulatory type 1 cells. Blood 2002, 100:2562-2571. 10.1182/blood-2001-12-0291, 12239170.
18. Bonanno G, Procoli A, Mariotti A, Corallo M, Perillo A, Danese S, De Cristofaro R, Scambia G, Rutella S. Effects of pegylated G-CSF on immune cell number and function in patients with gynecological malignancies. J Transl Med 2010, 8:114. 10.1186/1479-5876-8-114, 21062439.
19. Rutella S, Bonanno G, Pierelli L, Mariotti A, Capoluongo E, Contemi AM, Ameglio F, Curti A, De Ritis DG, Voso MT, Perillo A, Mancuso S, Scambia G, Lemoli RM, Leone G. Granulocyte colony-stimulating factor promotes the generation of regulatory DC through induction of IL-10 and IFN-a. Eur J Immunol 2004, 34:1291-1302. 10.1002/eji.200324651, 15114662.
20. Rutella S, Bonanno G, Procoli A, Mariotti A, de Ritis DG, Curti A, Danese S, Pessina G, Pandolfi S, Natoni F, Di Febo A, Scambia G, Manfredini R, Salati S, Ferrari S, Pierelli L, Leone G, Lemoli RM. Hepatocyte growth factor favors monocyte differentiation into regulatory interleukin (IL)-10++IL-12low/neg accessory cells with dendritic-cell features. Blood 2006, 108:218-227. 10.1182/blood-2005-08-3141, 16527888.
21. Arpinati M, Green CL, Heimfeld S, Heuser JE, Anasetti C. Granulocyte-colony stimulating factor mobilizes T helper 2-inducing dendritic cells. Blood 2000, 95:2484-2490. 10753825.
22. Hauge AW, Haastrup EK, Sengelov H, Minulescu L, Dickmeiss E, Fischer-Nielsen A. Addition of plerixafor for CD34+ cell mobilization in six healthy stem cell donors ensured satisfactory grafts for transplantation. Transfusion 2014, 54:1055-1058. 10.1111/trf.12383, 23944772.
23. Devine SM, Vij R, Rettig M, Todt L, McGlauchlen K, Fisher N, Devine H, Link DC, Calandra G, Bridger G, Westervelt P, Dipersio JF. Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction. Blood 2008, 112:990-998. 10.1182/blood-2007-12-130179, 18426988.
24. Neumann T, Kruger WH, Busemann C, Kiefer T, Dolken G. Successful mobilization of PBSCs in a healthy volunteer donor by addition of plerixafor after failure of mobilization with G-CSF alone. Bone Marrow Transplant 2011, 46:762-763. 10.1038/bmt.2010.178, 20676150.
25. Gaugler B, Arbez J, Legouill S, Tiberghien P, Moreau P, Derenne S, Saas P, Mohty M. Characterization of peripheral blood stem cell grafts mobilized by granulocyte colony-stimulating factor and plerixafor compared with granulocyte colony-stimulating factor alone. Cytotherapy 2013, 15:861-868. 10.1016/j.jcyt.2013.03.013, 23731764.
26. Bertaina A, Merli P, Rutella S, Pagliara D, Bernardo ME, Masetti R, Pende D, Falco M, Handgretinger R, Moretta F, Lucarelli B, Brescia LP, Li Pira G, Testi M, Cancrini C, Kabbara N, Carsetti R, Finocchi A, Moretta A, Moretta L, Locatelli F. HLA-haploidentical stem cell transplantation after removal of αβ+ T and B cells in children with non-malignant disorders. Blood 2014, 124:822-826. 10.1182/blood-2014-03-563817, 24869942.
27. Pierelli L, Maresca M, Piccirillo N, Pupella S, Gozzer M, Foddai ML, Vacca M, Adorno G, Coppetelli U, Paladini U. Accurate prediction of autologous stem cell apheresis yields using a double variable-dependent method assures systematic efficiency control of continuous flow collection procedures. Vox Sang 2006, 91:126-134. 10.1111/j.1423-0410.2006.00796.x, 16907873.
28. Whitby A, Whitby L, Fletcher M, Reilly JT, Sutherland DR, Keeney M, Barnett D. ISHAGE protocol: are we doing it correctly?. Cytometry B Clin Cytom 2012, 82:9-17. 10.1002/cyto.b.20612, 21915992.
29. Schumm M, Lang P, Bethge W, Faul C, Feuchtinger T, Pfeiffer M, Vogel W, Huppert V, Handgretinger R. Depletion of T-cell receptor αβ and CD19 positive cells from apheresis products with the CliniMACS device. Cytotherapy 2013, 15:1253-1258. 10.1016/j.jcyt.2013.05.014, 23993299.
30. Jackson SM, Wilson PC, James JA, Capra JD. Human B cell subsets. Adv Immunol 2008, 98:151-224. 10.1016/S0065-2776(08)00405-7, 18772006.
31. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999, 401:708-712. 10.1038/44385, 10537110.
32. Della Chiesa M, Falco M, Podesta M, Locatelli F, Moretta L, Frassoni F, Moretta A. Phenotypic and functional heterogeneity of human NK cells developing after umbilical cord blood transplantation: a role for human cytomegalovirus?. Blood 2012, 119:399-410. 10.1182/blood-2011-08-372003, 22096237.
33. Dzionek A, Fuchs A, Schmidt P, Cremer S, Zysk M, Miltenyi S, Buck DW, Schmitz J. BDCA-2, BDCA-3, and BDCA-4: three markers for distinct subsets of dendritic cells in human peripheral blood. J Immunol 2000, 165:6037-6046. 10.4049/jimmunol.165.11.6037, 11086035.
34. Schakel K, Kannagi R, Kniep B, Goto Y, Mitsuoka C, Zwirner J, Soruri A, von Kietzell M, Rieber E. 6-Sulfo LacNAc, a novel carbohydrate modification of PSGL-1, defines an inflammatory type of human dendritic cells. Immunity 2002, 17:289-301. 10.1016/S1074-7613(02)00393-X, 12354382.
35. Levesque JP, Hendy J, Takamatsu Y, Simmons PJ, Bendall LJ. Disruption of the CXCR4/CXCL12 chemotactic interaction during hematopoietic stem cell mobilization induced by GCSF or cyclophosphamide. J Clin Invest 2003, 111:187-196. 10.1172/JCI15994, 12531874.
36. Arpinati M, Chirumbolo G, Urbini B, Martelli V, Stanzani M, Falcioni S, Bonifazi F, Bandini G, Tura S, Baccarani M, Rondelli D. Use of anti-BDCA-2 antibody for detection of dendritic cells type-2 (DC2) in allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2002, 29:887-891. 10.1038/sj.bmt.1703569, 12080352.
37. Locatelli F, Merli P, Rutella S. At the Bedside: Innate immunity as an immunotherapy tool for hematological malignancies. J Leukoc Biol 2013, 94:1141-1157. 10.1189/jlb.0613343, 24096380.
38. Hainz U, Obexer P, Winkler C, Sedlmayr P, Takikawa O, Greinix H, Lawitschka A, Potschger U, Fuchs D, Ladisch S, Heitger A. Monocyte-mediated T-cell suppression and augmented monocyte tryptophan catabolism after human hematopoietic stem-cell transplantation. Blood 2005, 105:4127-4134. 10.1182/blood-2004-05-1726, 15677560.
39. Foley B, Cooley S, Verneris MR, Curtsinger J, Luo X, Waller EK, Weisdorf DJ, Miller JS. NK cell education after allogeneic transplantation: dissociation between recovery of cytokine-producing and cytotoxic functions. Blood 2011, 118:2784-2792. 10.1182/blood-2011-04-347070, 21757615.
40. Hansel A, Gunther C, Ingwersen J, Starke J, Schmitz M, Bachmann M, Meurer M, Rieber EP, Schakel K. Human slan (6-sulfo LacNAc) dendritic cells are inflammatory dermal dendritic cells in psoriasis and drive strong TH17/TH1 T-cell responses. J Allergy Clin Immunol 2011, 127:787-794. e781-789, 10.1016/j.jaci.2010.12.009, 21377044.
41. Kared H, Masson A, Adle-Biassette H, Bach JF, Chatenoud L, Zavala F. Treatment with granulocyte colony-stimulating factor prevents diabetes in NOD mice by recruiting plasmacytoid dendritic cells and functional CD4+CD25+ regulatory T-cells. Diabetes 2005, 54:78-84. 10.2337/diabetes.54.1.78, 15616013.
42. Lundqvist A, Smith AL, Takahashi Y, Wong S, Bahceci E, Cook L, Ramos C, Tawab A, McCoy JP, Read EJ, Khuu HM, Bolan CD, Joo J, Geller N, Leitman SF, Calandra G, Dunbar C, Kurlander R, Childs RW. Differences in the phenotype, cytokine gene expression profiles, and in vivo alloreactivity of T cells mobilized with plerixafor compared with G-CSF. J Immunol 2013, 191:6241-6249. 10.4049/jimmunol.1301148, 24244025.
43. MacDonald KP, Le Texier L, Zhang P, Morris H, Kuns RD, Lineburg KE, Leveque L, Don AL, Markey KA, Vuckovic S, Bagger FO, Boyle GM, Blazar BR, Hill GR. Modification of T cell responses by stem cell mobilization requires direct signaling of the T cell by G-CSF and IL-10. J Immunol 2014, 192:3180-3189. 10.4049/jimmunol.1302315, 24585878.
44. Morris ES, MacDonald KP, Hill GR. Stem cell mobilization with G-CSF analogs: a rational approach to separate GVHD and GVL?. Blood 2006, 107:3430-3435. 10.1182/blood-2005-10-4299, 16380448.
45. Sunami K, Teshima T, Nawa Y, Hiramatsu Y, Maeda Y, Takenaka K, Shinagawa K, Ishimaru F, Ikeda K, Niiya K, Harada M. Administration of granulocyte colony-stimulating factor induces hyporesponsiveness to lipopolysaccharide and impairs antigen-presenting function of peripheral blood monocytes. Exp Hematol 2001, 29:1117-1124. 10.1016/S0301-472X(01)00679-8, 11532353.
46. Frankenberger M, Hofer TP, Marei A, Dayyani F, Schewe S, Strasser C, Aldraihim A, Stanzel F, Lang R, Hoffmann R, Prazeres da Costa O, Buch T, Ziegler-Heitbrock L. Transcript profiling of CD16-positive monocytes reveals a unique molecular fingerprint. Eur J Immunol 2012, 42:957-974. 10.1002/eji.201141907, 22531920.
47. Cros J, Cagnard N, Woollard K, Patey N, Zhang SY, Senechal B, Puel A, Biswas SK, Moshous D, Picard C, Jais JP, D'Cruz D, Casanova JL, Trouillet C, Geissmann F. Human CD14dim monocytes patrol and sense nucleic acids and viruses via TLR7 and TLR8 receptors. Immunity 2010, 33:375-386. 10.1016/j.immuni.2010.08.012, 20832340.
48. Storek J, Espino G, Dawson MA, Storer B, Flowers ME, Maloney DG. Low B-cell and monocyte counts on day 80 are associated with high infection rates between days 100 and 365 after allogeneic marrow transplantation. Blood 2000, 96:3290-3293. 11050018.
49. Baumeister SH, Holig K, Bornhauser M, Meurer M, Rieber EP, Schakel K. G-CSF mobilizes slanDCs (6-sulfo LacNAc+ dendritic cells) with a high proinflammatory capacity. Blood 2007, 110:3078-3081. 10.1182/blood-2006-12-062984, 17616642.
50. Dar A, Schajnovitz A, Lapid K, Kalinkovich A, Itkin T, Ludin A, Kao WM, Battista M, Tesio M, Kollet O, Cohen NN, Margalit R, Buss EC, Baleux F, Oishi S, Fujii N, Larochelle A, Dunbar CE, Broxmeyer HE, Frenette PS, Lapidot T. Rapid mobilization of hematopoietic progenitors by AMD3100 and catecholamines is mediated by CXCR4-dependent SDF-1 release from bone marrow stromal cells. Leukemia 2011, 25:1286-1296. 10.1038/leu.2011.62, 21494253.
51. Gerlach LO, Skerlj RT, Bridger GJ, Schwartz TW. Molecular interactions of cyclam and bicyclam non-peptide antagonists with the CXCR4 chemokine receptor. J Biol Chem 2001, 276:14153-14160. 11154697.
52. Uy GL, Rettig MP, Motabi IH, McFarland K, Trinkaus KM, Hladnik LM, Kulkarni S, Abboud CN, Cashen AF, Stockerl-Goldstein KE, Vij R, Westervelt P, DiPersio JF. A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia. Blood 2012, 119:3917-3924. 10.1182/blood-2011-10-383406, 22308295.
53. Waller EK, Rosenthal H, Jones TW, Peel J, Lonial S, Langston A, Redei I, Jurickova I, Boyer MW. Larger numbers of CD4bright dendritic cells in donor bone marrow are associated with increased relapse after allogeneic bone marrow transplantation. Blood 2001, 97:2948-2956. 10.1182/blood.V97.10.2948, 11342416.
54. Reddy V, Iturraspe JA, Tzolas AC, Meier-Kriesche HU, Schold J, Wingard JR. Low dendritic cell count after allogeneic hematopoietic stem cell transplantation predicts relapse, death, and acute graft-versus-host disease. Blood 2004, 103:4330-4335. 10.1182/blood-2003-09-3325, 14962904.
55. Ziegler-Heitbrock L, Hofer TP. Toward a refined definition of monocyte subsets. Front Immunol 2013, 4:23. 10.3389/fimmu.2013.00023, 23382732.